Editas Medicine Inc. Equity-NMS: EDIT

Healthcare

Biotechnology

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :

$9.18

52W high :

$19.97

1Y :

-19.93%

5Y :

-75.13%

EPS(TTM): :

-3.18

Shares O/S :

69 M

Market cap :

658.91 M

What is the share price of Editas Medicine Inc. today?

Editas Medicine Inc. (EDIT) share price as of June 1, 2023, is $9.55. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of Editas Medicine Inc.?

Yes, Indian Investors can invest in the Editas Medicine Inc. (EDIT) Share by opening an international trading account with Angel One.

How can I purchase Editas Medicine Inc. shares in India?

Purchasing Editas Medicine Inc. (EDIT) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying Editas Medicine Inc. (EDIT) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of Editas Medicine Inc.?

Yes, you can purchase fractional shares of Editas Medicine Inc. (EDIT) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of Editas Medicine Inc.?

The market capitalization of Editas Medicine Inc. on June 1, 2023, is $658.91 M.

In which sector Editas Medicine Inc. belongs?

Editas Medicine Inc. operates in the Healthcare sector, specifically in the Biotechnology industry.

What documents are required to invest in Editas Medicine Inc. stocks?

In order to invest in Editas Medicine Inc. (EDIT) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing transformative gene editing medicines to treat a range of serious diseases. It has developed a gene editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cas12a), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. It is engaged in the development of in vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, EDIT-301, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta-thalassemia (TDT).